Marissa Alkhazov Quoted in Citeline

MoCRA Implementation Delay Creates More Legal Exposure For Stakeholders

By: Eileen Francis

Alkhazov explained the law “empowers and increases the FDA enforcement authority with mandatory recalls, facility suspensions and records access, which creates new potential exposure points for non-compliant companies, or companies who are kind of in that gray area and think they’re doing what needs to be done but they aren’t quite there. So that’s certainly a pain point with respect to the lack of final rules,” she said.

To read full article, click here.*

*Subscription may be required.